Prediction of pertussis vaccine efficacy using a correlates of protection model

Vaccine

Volumn 26, Issue 27-28, 2008, Pages 3516-3521

  Kohberger, Robert C ^a   Jemiolo, David ^b   Noriega, Fernando ^b  

^a Blair and Company   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

Pertussis; Serologic correlates of immunity; Vaccine efficacy

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; FIMBRIA PROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEMAGGLUTININ; IPOL; PENTACEL; PERTACTIN; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; SEROLOGY; VALIDATION STUDY;

HUMANS; MODELS, IMMUNOLOGICAL; MODELS, STATISTICAL; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 44749085856     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.016     Document Type: Article

References (12)

1. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 20 (1998) 1907-1916
2. Qin L., Gilbert P.B., Corey L., McElrath M.J., and Self S. A framework for assessing immunological correlates of protection in vaccine trials. JID 196 1 November (2007) 1304-1312
3. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350 9091 (1997) 1569-1577
4. Storsaeter J., Blackwelder W.C., and Hallander H.O. Pertussis antibodies, protection, and vaccine efficacy after household exposure. Am J Dis Child 146 2 (1992) 167-172
5. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1 8592 (1988) 955-960
6. Cherry J.D., Gornbein J., Heininger U., and Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 20 (1998) 1901-1906
7. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 6 (1996) 349-355
8. WHO meeting on case definition of pertussis, Geneva, January 10-11, 1991. Geneva: World Health Organization 1991:4-5 (issue no. MIM/EPI/PERT/91.1).
9. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 4 (1989) 431-440
10. In: Burzykowski T., Molenberghs G., and Buyse M. (Eds). The evaluation of surrogate endpoints (2005), Springer, New York
11. Chan I.S., Li S., Matthews H., Chan C., Vessey R., Sadoff J., et al. Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med 21 22 (2002) 3411-3430
12. Noriega F., Tsang P., Jemiolo D., Voloshen T., Greenberg D.P., and the Pentacel Investigators Study Group. Immunogenicity of a four-dose series of DTaP-IPV//PRP-T (Pentacel™). Poster session presented at: 5th pediatric infectious disease conference. Napa, CA, October (2005) [abstract 9]